| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a …
Over the last 12 months, insiders at IN8bio, Inc. have bought $0 and sold $0 worth of IN8bio, Inc. stock.
On average, over the past 5 years, insiders at IN8bio, Inc. have bought $1.66M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,500 shares for transaction amount of $2,375 was made by Graff Jeremy R. (director) on 2023‑09‑13.
| 2023-09-13 | Graff Jeremy R. | director | 2,500 0.0077% | $0.95 | $2,375 | +8.97% | ||
| 2023-08-25 | McCall Patrick | Chief Financial Officer | 1,000 0.0032% | $1.03 | $1,030 | +0.49% | ||
| 2023-08-24 | Ho William Tai-Wei | President and CEO | 23,800 0.0719% | $1.05 | $24,990 | +0.98% | ||
| 2022-12-12 | Kreis Leslie W. | director | 75,001 0.359% | $2.48 | $185,912 | -45.34% | ||
| 2022-12-12 | Fletcher Aaron G.L. | director | 75,001 0.359% | $2.48 | $185,912 | -45.34% | ||
| 2022-09-28 | Kreis Leslie W. | 25,000 0.1111% | $2.02 | $50,535 | -18.57% | |||
| 2022-09-28 | Fletcher Aaron G.L. | 25,000 0.1111% | $2.02 | $50,535 | -18.57% | |||
| 2022-08-26 | Cavu Advisors, LLC | 31,805 0.1513% | $2.02 | $64,232 | -5.36% | |||
| 2022-08-17 | Cavu Advisors, LLC | 38,035 0.1712% | $1.93 | $73,408 | -5.56% | |||
| 2022-08-17 | BIOS Advisors GP, LLC | 38,035 0.1712% | $1.93 | $73,408 | -5.56% | |||
| 2022-08-16 | Transcend Partners Opportunity Fund LLC | 789,473 3.713% | $1.90 | $1.5M | +0.53% | |||
| 2022-08-16 | Ho William Tai-Wei | President, CEO and CFO | 26,315 0.1238% | $1.90 | $49,999 | +0.53% | ||
| 2022-08-16 | Cavu Advisors, LLC | 206,575 0.9715% | $1.90 | $392,493 | +0.53% | |||
| 2022-08-16 | BIOS Advisors GP, LLC | 206,575 0.9715% | $1.90 | $392,493 | +0.53% | |||
| 2022-08-16 | Brandt Peter C. | 105,263 0.4951% | $1.90 | $200,000 | +0.53% | |||
| 2022-08-16 | Lamb Lawrence | EVP and CSO | 526 0.0025% | $1.90 | $999 | +0.53% | ||
| 2022-08-16 | Roemer Alan S. | 26,315 0.1238% | $1.90 | $49,999 | +0.53% | |||
| 2022-08-16 | Greenwood Luba | 526 0.0025% | $1.90 | $999 | +0.53% | |||
| 2022-08-16 | Rochlin Kate | Chief Operating Officer | 5,263 0.0248% | $1.90 | $10,000 | +0.53% | ||
| 2022-08-16 | McCall Patrick | Chief Financial Officer | 5,263 0.0248% | $1.90 | $10,000 | +0.53% |
| Transcend Partners Opportunity Fund LLC | 4111958 41.7103% | $3.91M | 1 | 0 | ||
| Fletcher Aaron G.L. | director | 3727597 37.8115% | $3.54M | 2 | 0 | |
| Kreis Leslie W. | director | 3727597 37.8115% | $3.54M | 2 | 0 | |
| Cavu Advisors, LLC | 3651528 37.0398% | $3.47M | 3 | 0 | ||
| BIOS Advisors GP, LLC | 3612569 36.6447% | $3.43M | 2 | 0 | ||
| FAIRBAIRN EMILY | 3322485 33.7021% | $3.16M | 1 | 0 | ||
| Ho William Tai-Wei | President and CEO | 2339545 23.7315% | $2.22M | 2 | 0 | +0.98% |
| Brandt Peter C. | 182473 1.8509% | $173,331.10 | 1 | 0 | ||
| Lamb Lawrence | EVP and CSO | 99730 1.0116% | $94,733.53 | 1 | 0 | |
| Roemer Alan S. | 55989 0.5679% | $53,183.95 | 1 | 0 | ||
| Greenwood Luba | 7826 0.0794% | $7,433.92 | 1 | 0 | ||
| McCall Patrick | Chief Financial Officer | 6263 0.0635% | $5,949.22 | 2 | 0 | +0.49% |
| Rochlin Kate | Chief Operating Officer | 5263 0.0534% | $4,999.32 | 1 | 0 | |
| Goswami Trishna | Chief Medical Officer | 2631 0.0267% | $2,499.19 | 1 | 0 | |
| Graff Jeremy R. | director | 2500 0.0254% | $2,374.75 | 1 | 0 | +8.97% |
$95,567,744 | 39 | -17.01% | $10.94M | |
$30,257,839 | 29 | -15.72% | $12M | |
$76,600 | 22 | -38.58% | $10.49M | |
$555,628 | 21 | 43.52% | $12.04M | |
$812,698 | 12 | -57.09% | $7.89M |
| Increased Positions | 13 | +59.09% | 2M | +243.66% |
| Decreased Positions | 10 | -45.45% | 164,953 | -16.83% |
| New Positions | 6 | New | 776,507 | New |
| Sold Out Positions | 4 | Sold Out | 69,259 | Sold Out |
| Total Postitions | 25 | +13.64% | 3M | +226.83% |
| Bios Capital Management, Lp | $705.00 | 5.73% | 286,664 | 0 | 0% | 2025-09-30 |
| Franklin Resources Inc | $467.00 | 3.8% | 189,894 | 0 | 0% | 2025-09-30 |
| Stonepine Capital Management, Llc | $392.00 | 3.19% | 159,421 | +76,991 | +93.4% | 2025-09-30 |
| Alyeska Investment Group, L.P. | $203.00 | 1.65% | 82,484 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $146.00 | 1.19% | 59,418 | -679 | -1.13% | 2025-09-30 |
| Two Sigma Investments, Lp | $122.00 | 0.99% | 49,453 | +49,453 | New | 2025-09-30 |
| Two Sigma Advisers, Lp | $113.00 | 0.92% | 45,751 | +45,751 | New | 2025-09-30 |
| Jane Street Group, Llc | $64.00 | 0.52% | 26,182 | +26,182 | New | 2025-09-30 |
| Citadel Advisors Llc | $61.00 | 0.5% | 24,728 | +24,728 | New | 2025-09-30 |
| Geode Capital Management, Llc | $47.00 | 0.39% | 19,292 | +472 | +2.51% | 2025-09-30 |